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Radiation therapy (RT) after breast conservation therapy has recently been linked with significant reduction in risk
of ipsilateral breast cancer among BRCA1 mutation carriers. However, the exact mechanism by which RT reduces
incidence of BRCA1-associated cancer remains unclear. Here we studied fresh breast tissue from a BRCA1 mutation
carrier who was initially treated with a lumpectomy and RT for a unilateral cancer and two years later chose a
prophylactic bilateral mastectomy while remaining cancer-free. Flow cytometry analysis demonstrated a strikingly
lower luminal cell population in the irradiated breast as compared to the non-irradiated breast, which was
confirmed by immunohistochemistry. Furthermore, the irradiated breast tissue exhibited very low progenitor cell
activity in vitro. Given the emerging evidence that BRCA1 tumors originate from luminal progenitor cells, our
observations suggest that preferential and long-lasting elimination of luminal ductal epithelium may partly underlie
the mechanism of RT-associated reduction in recurrence of BRCA1-associated cancer.
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Women who carry cancer-predisposing germ-line muta-
tions in BRCA1 have up to 80% chance of developing
breast cancer in their lifetime [1,2]. Narod and cowor-
kers recently reported that radiation therapy (RT) was
associated with a significant reduction in the risk of ipsi-
lateral breast cancer among BRCA1 mutation carriers
[3]. Although the exact mechanism by which radiation
affects breast cancer recurrence is not clear, it has trad-
itionally been thought to be due to killing of residual
tumor cells left behind after excision of the primary
tumor [4,5].
BRCA1-associated tumors usually have the “basal-like”
features and therefore had been presumed to originate
from basal stem cells. Surprisingly, recent work from
several laboratories suggests that BRCA1 tumors likely
originate from luminal progenitor cells [6-8]. Given the
well-documented role of BRCA1 in double-strand break
repair and radiation sensitivity [9,10], selective* Correspondence: lir3@uthscsa.edu
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reproduction in any medium, provided the orelimination of the cell of origin for BRCA1-associated
tumors could be an additional or alternative mechanism
by which RT reduces incidence of ipsilateral breast can-
cer in BRCA1 mutation carriers.
In the current study, we analyzed the abundance and
activity of luminal epithelial cells from irradiated and
non-irradiated breast tissue of a BRCA1 mutation carrier
who underwent bilateral prophylactic mastectomy. Our
result supports the notion that precancerous luminal
progenitor cells of BRCA1 mutation carriers are particu-
larly sensitive to radiation. The potential lineage-specific
radiosensitivity of cells from BRCA1 mutation carriers
could be exploited to develop novel prophylactic mea-
sures for this select group of at-risk women.Materials and methods
Isolation of human breast epithelial cells
Human breast tissue from mastectomy was dissociated
enzymatically with collagenase and hyaluronidase per
published procedure [11].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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According to a previously published protocol [6], mam-
mary cell suspension was pre-blocked and then labeled
with an allophycocyanin-conjugated rat antibody to CD49f
and FITC-conjugated mouse antibody to human EpCAM.
Lineage-negative hematopoietic and endothelial cells were
labeled with biotin-conjugated mouse antibodies to CD45,
CD235a and CD31, followed by pacific blue-conjugated
streptavidin. 7-ADD (BD Bioscience) was added to cells
before analysis for live/dead cell discrimination. Cell sort-
ing was performed on a FACSAria flow cytometer (Becton
Dickinson). Cells were sorted into four fractions as follows:
EpCAM- CD49f stromal cells, EpCAMlow CD49fhigh basal
epithelial cells, EpCAMhigh CD49f+ luminal progenitor cells,
and EpCAMhigh CD49f- mature luminal epithelial cells.
Immunohistochemistry
Immunohistochemistry of formalin-fixed paraffin-em-
bedded samples was carried out with a commercially
available ADH5 staining kit (Cat. # PM360DSAA,H; Bio-
care Medical).
In vitro mammary colony-forming cell assay
Sorted epithelial cells obtained from primary breast tis-




Figure 1 Irradiated breast tissue has a diminished luminal compartme
non-irradiated and irradiated breasts of a BRCA1 mutation carrier. (B). Immu
(brown) than luminal cells (red) in irradiated vs. non-irradiated breast glanddescribed [12]. After culturing for 7–12 days, cells were
briefly fixed with methanol and acetone, stained with
Wright’s Giemsa; and colonies were visually scored
under a dissecting microscope.
Case presentation
A BRCA1 mutation carrier initially received a lumpectomy
with histologically negative margins and whole-breast RT
(5040 cGy in 28 fractions) for a unilateral cancer in the
right breast, and was subsequently found to have a cancer-
predisposing BRCA1 mutation (4987C>G). After learning
the results of the genetic testing, the patient chose to
have a bilateral mastectomy two years after her original
treatment, while remaining cancer-free. Upon obtaining
an Institutional Review Board (IRB)-approved informed
consent, fresh cancer-free tissue from the non-irradiated
and irradiated breasts was obtained at the time of sur-
gery and immediately processed in parallel for single-cell
isolation [11]. Simultaneous comparison of bilateral breast
tissue from the same person allowed us to exclude
individual-based variation.
Fluorescence-activated cell sorting (FACS) using estab-
lished cell surface markers [6,12-14] identified four distinct
lineage-negative cell populations, namely, mature luminal
epithelial cells (EpCAMhighCD49f-), luminal progenitorIrradiated 
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nt. A. Flow cytometry analysis of cancer-free tissue from the



































Figure 2 Reduced progenitor cell activity in the previously
irradiated breast tissue. An equal number of live epithelial cells
from the non-irradiated and irradiated breasts were plated together
with γ-irradiated NIH 3T3 feeder cells. The images were taken a
week after culturing.
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and basal epithelial cells (EpCAMlowCD49fhigh). The purity
of the sorted cells was validated by qRT-PCR analysis of
mRNA species that are enriched in stromal (vimentin),
luminal (keratin 18), and basal cells (keratin 14) (data not
shown). The FACS profile indicated that the previously
irradiated breast contained much lower percentages of
mature luminal cells (0.926% vs. 21.5%; top right in
Figure 1A) and luminal progenitor cells (0.599% vs.
5.34%; top right in Figure 1A) than the non-irradiated
breast. This represents a 95% and 89% reduction in these
two luminal epithelial cell populations, respectively.
Histologic examination shows atrophic lobules in the
irradiated breast, in contrast to proliferative fibrocystic
changes in the non-irradiated breast. Consistent with the
FACS result, immunohistochemistry with a cocktail of
antibodies for luminal and basal/myoepithelial markers
(ADH5; Figure 1B) indicates a reduced ratio of luminal
over basal/myoepithelial cell populations in the irradiated
breast (1.422 ± 0.410 (s.d.) for non-irradiated; 0.375 ±
0.155 (s.d.) for irradiated; p = 0.0014).
Next, we used an established mammary colony-
forming cell (Ma-CFC) assay [12], [13] to enumerate the
progenitor cells of the sorted epithelial cell populations.
An equal number (200/cm2; 800 cells/well) of live epi-
thelial cells from the non-irradiated and irradiated breast
samples were seeded together with NIH 3T3 feeder cells.
Consistent with published results [14], both the
EpCAMlowCD49fhigh and EpCAMhighCD49f+, but not
EpCAMhighCD49f-, fractions from the non-irradiated
breast gave rise to cell colonies (Figure 2). In stark con-
trast, none of the three epithelial fractions from the pre-
viously irradiated breast produced any colonies. This
result strongly suggests that the previously irradiated
breast of the BRCA1 mutation carrier has substantially
diminished progenitor cell activity.
Discussion and conclusion
RT is associated with reduced recurrence of sporadic
[15,16] as well as BRCA1-associated breast cancer [3]. In
fact, whole-breast low-dose RT has been proposed as an
alternative to prophylactic mastectomy [17]. Historically,
RT was thought to primarily target residual tumor cells
left behind after excision of the primary tumor, despite
histologically cancer-free margins [4,5]. While this
remains a viable hypothesis, our finding that RT is asso-
ciated with a dramatically reduced luminal compartment
and diminished progenitor cell activity provides an add-
itional possible mechanism by which RT could reduce
incidence of cancer recurrence. Our observation is con-
sistent with the notion that radiation reduces the num-
ber of non-cancerous luminal progenitor cells, the likely
cell of origin for BRCA1-associated tumors, thus leading
to reduced cancer incidence.There are several limitations in the current study.
First, while our data indicate a relatively larger fraction
of basal/myoepithelial cells in the irradiated breast, it is
unclear whether this was due to an absolute increase in
their number or a relative effect due to the decrease in
luminal progenitor cells. However, the similarity in the
abundance of the stromal proportion in both breasts
argues that there were absolute changes in number of
both epithelial compartments. Second, whether the
changes observed in our study are unique to breast epi-
thelial cells from BRCA1 mutation carriers needs to be
determined. In addition, it is important to validate these
results when more samples of BRCA1 patients with
similarly uncommon confluence of events become avail-
able. However, since these results are consistent across
disparate technological and methodological platforms,
including FACS, IHC, and the cell-based functional
assay, it is unlikely that they are due to chance alone.
Lastly, we do not know the long-term effects of RT on
the breast cancer incidence for the particular individual
involved in the study.
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break repair, as demonstrated in numerous in vitro sys-
tems, is in stark contrast to its highly tissue-specific na-
ture as a tumor suppressor. Consistent with this, there
are no reports of excessive radiosensitivity in skin or con-
nective tissue of BRCA1 mutation carriers who receive
RT. Likewise, we did not observe any significant differ-
ence between the stromal cell populations of the irra-
diated and non-irradiated breast samples. Therefore,
radiosensitivity of cells from BRCA1 mutation carriers
may depend on their tissue location, differentiation
lineage, and developmental stage. As our study was con-
ducted two years after RT, the observed difference is most
likely long-term, not acute, effects of radiation. This is an
especially important consideration when exploring a
radiation-based preventive approach.
In conclusion, our study reveals an interesting associ-
ation between RT and reduced luminal epithelial popula-
tion in the breast tissue of a BRCA1 mutation carrier.
The potential vulnerability of luminal epithelial cells to
RT could be the “Achilles’ heel” for the cell of origin of
BRCA1-associated tumors, exploitation of which may
guide the development of novel preventive options for
this very select patient population.
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